UCB 35440

Drug Profile

UCB 35440

Alternative Names: UCB 35440-3

Latest Information Update: 05 Aug 2004

Price : $50

At a glance

  • Originator UCB
  • Class Antiallergics; Antiasthmatics; Piperazines
  • Mechanism of Action 5-lipoxygenase inhibitors; Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Allergic rhinitis; Asthma

Most Recent Events

  • 05 Aug 2004 Suspended - Phase-II for Asthma (PO)
  • 05 Aug 2004 Suspended - Phase-I for Allergic rhinitis (PO)
  • 21 Jun 2004 Data presented at the 100th International Conference of the American Thoracic Society (ATS-2004) have been added to the Respiratory disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top